SeaCrest Wealth Management’s Anavex Life Sciences AVXL Stock Holding History

SeaCrest Wealth Management’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-19,700	Closed	-$182K	–	633
2025 Q2	$182K	Buy	19,700 +2,100	+12%	+$17.9K	0.02%	588
2025 Q1	$151K	Buy	17,600 +2,300	+15%	+$21.7K	0.02%	635
2024 Q4	$164K	Buy	+15,300	New	+$118K	0.02%	628
2022 Q3	–	Sell	-4,375	Closed	-$44K	–	691
2022 Q2	$44K	Buy	+4,375	New	+$41.4K	0.01%	1171
2022 Q1	–	Sell	-13,075	Closed	-$227K	–	717
2021 Q4	$227K	Sell	13,075 -1,400	-10%	-$26.6K	0.02%	604
2021 Q3	$260K	Buy	14,475 +650	+5%	+$12.9K	0.03%	533
2021 Q2	$316K	Buy	+13,825	New	+$205K	0.04%	484

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

SeaCrest Wealth Management's AVXL Position: Q3 2025 in Review

SeaCrest Wealth Management sold out of Anavex Life Sciences (AVXL) in Q3 2025, closing a stake of 19,700 shares — an estimated $182K sold.

SeaCrest Wealth Management first reported a position in AVXL in Q2 2021 and held it in 7 quarters. The position peaked at $316K in Q2 2021. 186 funds tracked by Wall St. Rank hold AVXL as of Q3 2025.

SeaCrest Wealth Management reported no remaining Anavex Life Sciences position as of Q3 2025 after selling out during the quarter.
SeaCrest Wealth Management sold 19,700 Anavex Life Sciences shares in Q3 2025, an estimated $182K.
SeaCrest Wealth Management first reported a position in Anavex Life Sciences in Q2 2021 and held it in 7 quarters.
SeaCrest Wealth Management's Anavex Life Sciences position peaked at $316K in Q2 2021.
186 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2025.

Based on SeaCrest Wealth Management's 13F filing for Q3 2025, filed 13 Nov 2025.